Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™

Exclusion Criteria

• •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the vaccination, or planned use during the study period.
• •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before study vaccination and during the entire study period.
• •Administration of any pneumococcal vaccine since the end of study NCT00333450.
• •Administration of immunoglobulins and/or any blood products less than 3 months prior to the vaccination or planned use during the study period.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical
• •History of any neurologic disorders or seizures
• •Anaphylactic reaction following previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
• •History of hypotonic-hyporesponsive episode after any previous vaccination.
• •Major congenital defects or serious chronic illness.
• •History of invasive pneumococcal diseases.
• •Acute disease at the time of vaccination
• •Rectal temperature \>= 38.0°C or oral/axillary/tympanic temperature \>= 37.5°C. A temperature greater than or equal to these cut-offs warrants deferral of the vaccination pending recovery of the subject.